

DNDi R&D PORTFOLIO DECEMBER 2022 – 12 TREATMENTS DELIVERED



	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
Sleeping sickness							Acoziborole +	Fexinidazole for <i>T.b. rhodesiense</i> +	Fexinidazole for <i>T.b. gambiense</i> * +
									Nifurtimox-eflornithine combination therapy (NECT)*
Leishmaniasis	Screening		S07 series +	DNDI-6174 +	DNDI-6148 +	LXE408 Novartis +	New CL combination	Miltefosine + paromomycin combination (Africa)	SSG&PM (East Africa)*
					DNDI-0690 +		New treatments for PKDL		New VL treatments (South Asia)*
					GSK899 DDD853651 +				New treatments for HIV/VL*
					CpG-D35 for CL +				New VL treatments (Latin America)
					GSK245 DDD1305143 +				
Chagas disease	Screening	Hit-to-lead	UW series +	Biomarkers	DNDI-6148 +		New benznidazole regimens	Benznidazole paediatric dosage forms*	
Filaria: River blindness				CC6166 +	Oxfendazole +	Emodepside +			
						Flubentylosin +			
Mycetoma							Fosravuconazole		
Dengue				Pre-clinical profiling					
HIV						Sustained-release 5FC (cryptococcal meningitis)			Super-booster for children with HIV/TB*
									4-in-1 (ABC/3TC/LPV/r)*
									2-in-1 LPV/r pellets
									5 FC, LamB access (cryptococcal meningitis)
Hepatitis C							Ravidasvir + sofosbuvir +	Ravidasvir* and other DAAs +	
COVID-19/ Pandemic preparedness	Nucleo- side Booster		TMEM16 series +	Pre-clinical support			ANTICOV		
			Moonshot +						
			AVIDD ASAP +						
Malaria >>									Fixed-dose combination ASMQ*
									Fixed-dose combination ASAQ*

>> Implementation transferred to the Medicines for Malaria Venture in 2015

+ NCE (New Chemical Entity)

* Treatments delivered by DNDi with partners

> Treatments not delivered by DNDi, but DNDi working on access